2024-11-20 04:38:37
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
Corporate/ 2023-07-24
Everest Medicines' Licensing Partne...

FOSTER CITY,Calif. and SHANGHAI,June 4,2022-- Everest Medicines (HKEX 1952.HK) announces today that its licensing partner,Gilead Sciences,In...

Innovent Presents Clinical Data of Phase I Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Corporate/ 2023-07-24
Innovent Presents Clinical Data of Phase...

SAN FRANCISCO and SUZHOU,China,June 6,2022-- Innovent Biologics,Inc. ("Innovent") (HKEX: 01801),a world-class biopharmaceutical co...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release